ASCO Gastrointestinal Cancers Symposium

CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer

January 25th 2025, 5:43pm

Article

Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.

Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC

January 25th 2025, 4:00pm

Article

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.

Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer

January 25th 2025, 3:02pm

Article

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.

Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract

January 24th 2025, 8:39pm

Article

A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.

Bezuclastinib Plus Sutent May Be Safe and Effective in GIST

January 24th 2025, 6:30pm

Article

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis

January 24th 2025, 5:18pm

Article

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.

Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers

January 24th 2025, 2:00pm

Article

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.

Opdivo Plus Chemo Shows 5-Year Efficacy in Gastric, GEJ and Esophageal Cancer

January 23rd 2025, 10:15pm

Article

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

SHR-1701 Combo Reduces Chemo-Related Myelosuppression in Gastric/GEJ Cancer

January 23rd 2025, 9:35pm

Article

SHR-1701 plus chemo suppressed chemo-associated myelosuppression in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Afinitor Plus Somatuline Prolongs Survival in GEP-NETs

January 23rd 2025, 7:00pm

Article

Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.